Grifols SA ADR (GRFS) Stock Analysis

Grifols SA ADR (GRFS) is a publicly traded company in the HEALTHCARE sector. It trades at $7.63, carries a market capitalization of $5.27B, a price-to-earnings ratio of 10.90, a dividend yield of 0.02%. This page summarizes the public market data, fundamentals, and frequently asked questions for GRFS, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - DRUG MANUFACTURERS - GENERAL

Exchange: NASDAQ

Key Metrics

Market Sentiment

Grifols SA ADR currently has a Neutral sentiment score of 0.09.

About Grifols SA ADR

Grifols, SA (Ticker: GRFS) is a prominent global player in the pharmaceutical and biotechnology sectors, recognized for its expertise in the development and distribution of life-saving therapies derived from human plasma. Based in Barcelona, Spain, the company operates a robust network of plasma donation centers and state-of-the-art manufacturing facilities, enabling it to address the needs of patients with rare and chronic diseases effectively. Grifols is committed to innovating healthcare s...

GNG Research Analysis

GNG Research scores Grifols SA ADR (GRFS) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for GRFS.

Frequently Asked Questions

What is GRFS's current dividend yield?

Grifols SA ADR (GRFS) has a current dividend yield of 0.02%.

Does GRFS pay dividends?

Yes, Grifols SA ADR pays dividends with a current yield of 0.02%.

What is GRFS's P/E ratio?

Grifols SA ADR has a price-to-earnings (P/E) ratio of 10.90.

What is GRFS's market cap?

Grifols SA ADR (GRFS) has a market capitalization of $5.27B with a current stock price of $7.63.